Sector: Healthcare / Cannabis
Platform: Republic Europe
Stage: Crowdfunding
What They Do
SWISSCAN cultivates pharmaceutical-grade cannabis under a Swiss license and prepares GMP-certified products for distribution to pharmacies across the European Union.
Why It Might Be the Next Big Thing
With the European medical cannabis market projected to reach billions in value, SWISSCAN is positioning itself early with regulatory compliance, pharma distribution partners, and a vertically integrated facility already built in Switzerland. The company aims to fill a gap in standardized, high-quality supply across the EU.
Snapshot
Founded by European entrepreneurs with €4M in self-funding
Prepping for EU-GMP certification to supply pharmacies
Republic Europe campaign exceeded target
Facility built to pharmaceutical standards with Swiss cultivation license
Who’s Backing Them
Public investors via Republic Europe; no institutional names disclosed
My Take
Cannabis startups often chase volume—SWISSCAN is chasing pharmaceutical precision. If they secure GMP status, they’ll be one of the few ready to scale legally and logistically in Europe.
📖 Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice or investment solicitation.